<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4301</id>
  <title>T3D4247</title>
  <common-name>L-2-Hydroxyglutaric acid</common-name>
  <description>L-2-Hydroxyglutaric acid is an alpha hydroxy acid. In humans the compound is formed by a hydroxyacid-oxoacid transhydrogenase whereas in bacteria is formed by a 2-hydroxyglutarate synthase. The compound can be converted to α-ketoglutaric acid through the action of a 2-hydroxyglutarate dehydrogenase. In humans, there are two such enzymes called D2HGDH and L2HGDH. Tissue accumulation of high amounts of D-2-hydroxyglutaric acid is the biochemical hallmark of the inherited neurometabolic disorder D-2-hydroxyglutaric aciduria. Both the D and the L stereoisomers of hydroxyglutaric acid (EC 1.1.99.2) are found in body fluids. Accumulation of L-2-hydroxyglutaric acid has been reported in multiple patients who have a clinical phenotype of progressive neurodegeneration with extrapyramidal and cerebellar signs, seizures, and spongiform changes in the white matter. Patients who have excess accumulation of D-2-hydroxyglutaric acid in the urine exhibit a variable phenotype but included mental retardation, macrocephaly with cerebral atrophy, hypotonia, seizures, and involuntary movements.</description>
  <cas>13095-48-2</cas>
  <pubchem-id>439939</pubchem-id>
  <chemical-formula>C5H8O5</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point></melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility></solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Endogenous, Injection</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>2-hydroxyglutarate is an oncometabolite. It is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases. As a result, high levels of 2-hydroxyglutarate lead to genome-wide histone and DNA methylation alterations, which in turn lead to mutations that ultimately cause cancer. L-2-hydroxyglutarate mediates its neurotoxicity through activation of N-methyl-D-aspartate receptors. L-2-hydroxyglutarate is structurally similar to the excitatory amino acid glutamate and stimulates neurodegeneration by mechanisms well-known for glutamate, NMDA or mitochondrial toxins (A15198).</mechanism-of-toxicity>
  <metabolism></metabolism>
  <toxicity></toxicity>
  <lethaldose></lethaldose>
  <carcinogenicity>Not listed by IARC. Has been implicated in oncogenesis (A15091, A15090).</carcinogenicity>
  <use-source></use-source>
  <min-risk-level></min-risk-level>
  <health-effects>Chronically high levels of L-2-hydroxyglutaric acid are associated with the inborn error of metabolism called: 2-Hydroxyglutaric Aciduria. L-2-hydroxyglutarate is neurotoxic. L-2-hydroxyglutarate mediates its neurotoxicity through activation of N-methyl-D-aspartate receptors. Symptoms of L-2-Hydroxyglutaric Aciduria include hypotonia, tremors, and epilepsy declining into spongiform leukoencephalopathy, muscular choreodystonia, mental retardation, and psychomotor regression.</health-effects>
  <symptoms>Chronic exposure of high levels of L-2-hydroxyglutarate leads to hypotonia, tremors, and epilepsy declining into spongiform leukoencephalopathy, muscular choreodystonia, mental retardation, and psychomotor regression.</symptoms>
  <treatment></treatment>
  <created-at type="dateTime">2014-08-29T06:03:11Z</created-at>
  <updated-at type="dateTime">2026-04-06T11:40:12Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia></wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C03196</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>32797</chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id></ctd-id>
  <stitch-id></stitch-id>
  <drugbank-id></drugbank-id>
  <pdb-id>S2G</pdb-id>
  <actor-id></actor-id>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>[H][C@](O)(CCC(O)=O)C(O)=O</moldb-smiles>
  <moldb-formula>C5H8O5</moldb-formula>
  <moldb-inchi>InChI=1S/C5H8O5/c6-3(5(9)10)1-2-4(7)8/h3,6H,1-2H2,(H,7,8)(H,9,10)/t3-/m0/s1</moldb-inchi>
  <moldb-inchikey>HWXBTNAVRSUOJR-VKHMYHEASA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">148.114</moldb-average-mass>
  <moldb-mono-mass type="decimal">148.037173366</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp></logp>
  <hmdb-id>HMDB00694</hmdb-id>
  <chembl-id>CHEMBL1615211</chembl-id>
  <chemspider-id>388969</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>Kobayashi, Hidehiko; Yamaguchi, Koretaka; Yamashita, Takeshi.  a-Hydroxyglutaric acid from glutamic acid.    Jpn. Tokkyo Koho  (1968),     3 pp.</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003207</chemdb-id>
  <dsstox-id nil="true"/>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00122108</susdat-id>
  <iupac nil="true"/>
  <moldb-polar-surface-area>94.83000000000001</moldb-polar-surface-area>
  <moldb-refractivity>29.6302</moldb-refractivity>
  <moldb-polarizability>12.9730498807228</moldb-polarizability>
  <moldb-rotatable-bond-count>4</moldb-rotatable-bond-count>
  <moldb-acceptor-count>5</moldb-acceptor-count>
  <moldb-donor-count>3</moldb-donor-count>
  <moldb-pka-strongest-acidic>3.276485914460605</moldb-pka-strongest-acidic>
  <moldb-pka-strongest-basic>-3.8068384384876675</moldb-pka-strongest-basic>
  <moldb-physiological-charge>-2</moldb-physiological-charge>
  <moldb-number-of-rings>0</moldb-number-of-rings>
  <moldb-alogps-logp>-1.04</moldb-alogps-logp>
  <moldb-alogps-logs>0.03</moldb-alogps-logs>
  <moldb-alogps-solubility>1.57e+02 g/l</moldb-alogps-solubility>
</compound>
